Skip to main
DNTH
DNTH logo

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc is well-positioned for growth, highlighted by the substantial expansion of the complement franchise in the broader market, which reached $6.5 billion in 2024, primarily driven by treatment-naive myasthenia gravis patients. The company’s lead candidate, DNTH103, is anticipated to demonstrate a favorable safety profile supported by positive Phase 2 data from riliprubart, suggesting strong clinical potential in managing autoimmune disorders. Moreover, with upcoming data readouts expected in the next 18 months and a growing enthusiasm among key opinion leaders for the company’s unique approach to monoclonal antibodies, Dianthus Therapeutics is set to enhance its competitive position in the biotechnology sector.

Bears say

Dianthus Therapeutics Inc. reported a substantial net loss of $28.4 million for the fourth quarter, translating to a loss of $0.81 per share, which may raise concerns about the company's financial sustainability given its high research and development expenses of $26.4 million. The reliance on external financing poses a significant risk, particularly if the company encounters delays or failures in its clinical trials, or if unexpected safety issues arise, potentially hindering the advancement of its therapeutic pipeline. Furthermore, the pressure of emerging competition and continued reliance on market capital raises additional uncertainties regarding the company's long-term viability in the biotech sector.

DNTH has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Buy based on their latest research and market trends.

According to 5 analysts, DNTH has a Buy consensus rating as of Sep 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.